A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects With Advanced Solid Tumors
Latest Information Update: 29 Apr 2022
At a glance
- Drugs CS 3005 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors CStone Pharmaceuticals
- 26 Apr 2022 Status changed from recruiting to completed.
- 22 Jan 2020 New source identified and integrated: ClinicalTrials.gov: US National Institutes of Health (NCT04233060).
- 18 Dec 2019 New trial record